Verséa Health, Inc. - Verséa
 
HomeAuthor

Verséa Health, Inc.

Verséa Health, Inc. Acquires ISO 9001 Certification

TAMPA, FL., June 6, 2024 — Verséa Health, Inc. (“Verséa”), a Florida-based transformative health care company specializing in the commercialization of innovative diagnostics, therapeutics, and health services, has successfully acquired the ISO 9001 certification. Securing ISO 9001 certification across all three Verséa Health’s strategic business units – Diagnostics, Ophthalmics, and Discovery – represents a substantial accomplishment....

WEST POINT OPTICAL GROUP, LLC AND VERSÉA OPHTHALMICS, INC. ANNOUNCE PARTNERSHIP SUPPLY AGREEMENT FOR  BIOVANCE®AND BIOVANCE® 3L OCULAR

MASON, OH and TAMPA, FL., April 3, 2024 — West Point Optical Group, LLC (“WPOG”), providing quality patient care by developing experienced, well-rounded vision health teams within its 86 Pearle Vision stores, and Verséa Ophthalmics, Inc. (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, today announced...

Verséa Ophthalmics and Celularity Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications

TAMPA, FL. and FLORHAM PARK, N.J., July 27, 2023 — Verséa Ophthalmics, LLC (“Verséa Ophthalmics”), a Tampa, FL-based company that focuses on providing complete ocular point-of-care diagnostic and therapeutic interventions, and Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that the companies have entered into...

Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform

7/25/2022, Tampa, FL – Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow  Readers. The company focuses on delivering innovative Tear-based Point-of-Care (T-POC) testing and biologic solutions that...

Verséa Health and iRemedy Announce Strategic Joint Venture

Tampa, FL – June 28, 2023 – Verséa Health, Inc., a prominent provider of diagnostics and medical supplies for urgent care centers, and iRemedy Healthcare Companies, Inc. (“iRemedy”), a trailblazer in the medical supply e-commerce industry, are thrilled to announce their strategic joint venture. The collaboration aims to establish an integrated ecosystem of services tailored...

Verséa Health and Doc Johnson to Launch Wellness Center for Retailers

Tampa, FL. — Verséa Health, Inc. has partnered with Doc Johnson to launch a new Doc Johnson Wellness Center display available to retailers. This exclusive new partnership will provide Doc Johnson customers with access to cutting-edge diagnostics, treatments and preventive care services that are tailored to their individual needs. The Doc Johnson Wellness Center will include...

Uncovering The Truth Behind Healthcare Systems with Sean Fetcho, Co-Founder & CEO of Verséa™ Health

We are pleased to announce that our Co-Founder and CEO, Sean Fetcho, was recently featured as a guest on the Healthcare Executive Insights Podcast, presented by The Macallan Group. The latest episode titled “Uncovering The Truth Behind Healthcare Systems” is now available for streaming on YouTube, Spotify, and Apple Podcasts. During the podcast, Sean shares...

Verséa™ Biologics at the North American Neuromodulation Society 26th Annual Meeting

Members of our Verséa Biologics team (Sunil Panchal, MD, Chief Scientific Officer, Verséa Biologics; David Kloth, M.D., Medical Director, Verséa Biologics; and Bill Bigham, VP of Sales, Verséa Biologics) attended this year’s North American Neuromodulation Society 26th Annual Meeting. At the event they had a chance to present our innovative portfolio of Biologics products which...